High white blood cell count at diagnosis of childhood acute lymphoblastic leukaemia: Biological background and prognostic impact. Results from the NOPHO ALL-92 and ALL-2000 studies

European Journal of Haematology

Volumn 86, Issue 1, 2011, Pages 38-46

  Vaitkevičiene, Goda ^a,b   Forestier, Erik ^c   Hellebostad, Marit ^d   Heyman, Mats ^e   Jonsson, Olafur G ^f   Lähteenmäki, Päivi M ^g   Rosthoej, Susanne ^h   Söderhäll, Stefan ^e   Schmiegelow, Kjeld ^b,i  

^a Centre for Paediatric Oncology and Haematology   (Lithuania)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c UMEÅ UNIVERSITY   (Sweden)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acute lymphoblastic leukaemia; Children; Minimal residual disease; Prognostic factors; Survival; White blood cell

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ERWINIA ASPARAGINASE; ESCHERICHIA COLI ASPARAGINASE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CYTOGENETICS; DENMARK; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG SUBSTITUTION; FEMALE; FINLAND; HIGH RISK PATIENT; HUMAN; ICELAND; INFANT; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NORWAY; OVERALL SURVIVAL; PRE T LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SWEDEN;

EID: 78650084205     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01522.x     Document Type: Article

References (37)

1. Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD, Bleyer WA. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;14:2223-33.
2. Eden OB, Harrison G, Richards S, Lilleyman JS, Bailey CC, Chessells JM, Hann IM, Hill FG, Gibson BE. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia 2000;14:2307-20.
3. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, Gadner H, Odenwald E, Riehm H. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000;14:2205-22.
4. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000;14:2286-94.
5. Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007;109:926-35.
6. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G, Mellander L, Makipernaa A, Nygaard R, Saarinen-Pihkala UM. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000;14:2267-75.
7. Forestier E, Schmiegelow K. The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations. J Pediatr Hematol Oncol 2006;28:486-95.
8. Sinnett D, Labuda D, Krajinovic M. Challenges identifying genetic determinants of pediatric cancers - the childhood leukemia experience. Fam Cancer 2006;5:35-47.
9. Forestier E, Johansson B, Gustafsson G, Borgstrom G, Kerndrup G, Johannsson J, Heim S. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periods. For the Nordic Society of Paediatric Haematology and Oncology (NOPHO) Leukaemia Cytogenetic Study Group. Br J Haematol 2000;110:147-53.
10. Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen N, Wesenberg F, Jonsson OG, Forestier E, Schmiegelow K. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002;99:1253-8.
11. Ratei R, Basso G, Dworzak M, Gaipa G, Veltroni M, Rhein P, Biondi A, Schrappe M, Ludwig WD, Karawajew L. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia 2009;23:528-34.
12. Irving J, Jesson J, Virgo P, et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica 2009;94:870-4.
13. Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002;100:52-8.
14. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, Van't Veer MB. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783-6.
15. Forestier E, Heyman M, Andersen MK, et al. Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival. Br J Haematol 2008;140:665-72.
16. Mitelman F. An International System for Human Cytogenetic Nomenclature. Basel: S. Karger, 1995.
17. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S, Taskinen M. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010;24:345-54.
18. Saarinen-Pihkala UM, Gustafsson G, Carlsen N, Flaegstad T, Forestier E, Glomstein A, Kristinsson J, Lanning M, Schroeder H, Mellander L. Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation. Pediatr Blood Cancer 2004;42:8-23.
19. Schmiegelow K, Bjork O, Glomstein A, et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:1332-9.
20. Skarby TV, Anderson H, Heldrup J, Kanerva JA, Seidel H, Schmiegelow K. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 2006;20:1955-62.
21. Siegel S, Castellan NJ. Nonparametric Statistics for the Behavioral Sciences, 2nd edn. Singapore: McGraw-Hill Publishing Co., 1988.
22. Kaplan EJ, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
23. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc (B) 1972;34:187-220.
24. Andersen PK, Borgan Ø, Gill RD, Keiding N. Statistical Models Based on Counting Processes. New York: Springer-Verlag, 1993.
25. Cooperman J, Neely R, Teachey DT, Grupp S, Choi JK. Cell division rates of primary human precursor B cells in culture reflect in vivo rates. Stem Cells 2004;22:1111-20.
26. Bhojwani D, Kang H, Menezes RX, et al. Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: a Children's Oncology Group Study [corrected]. J Clin Oncol 2008;26:4376-84.
27. Ito C, Kumagai M, Manabe A, Coustan-Smith E, Raimondi SC, Behm FG, Murti KG, Rubnitz JE, Pui CH, Campana D. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. Blood 1999;93:315-20.
28. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 2009;144:147-56.
29. Flotho C, Coustan-Smith E, Pei D, Cheng C, Song G, Pui CH, Downing JR, Campana D. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood 2007;110:1271-7.
30. Suzuki T, Coustan-Smith E, Mihara K, Campana D. Signals mediated by FcgammaRIIA suppress the growth of B-lineage acute lymphoblastic leukemia cells. Leukemia 2002;16:1276-84.
31. Noren-Nystrom U, Roos G, Bergh A, Botling J, Lonnerholm G, Porwit A, Heyman M, Forestier E. Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome. Leukemia 2008;22:504-10.
32. Calado RT, Yewdell WT, Wilkerson KL, Regal JA, Kajigaya S, Stratakis CA, Young NS. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 2009;114:2236-43.
33. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A. Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood 2009;113:3287-96.
34. Pui CH, Chessells JM, Camitta B, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 2003;17:700-6.
35. Harbott J, Mancini M, Verellen-Dumoulin C, Moorman AV, Secker-Walker LM. Hematological malignancies with a deletion of 11q23: cytogenetic and clinical aspects. European 11q23 Workshop participants. Leukemia 1998;12:823-7.
36. Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-Walker LM. Hematological malignancies with t(9;11)(p21-22;q23) - a laboratory and clinical study of 125 cases. European 11q23 Workshop participants. Leukemia 1998;12:792-800.
37. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010;115:3206-14.